Bp Plc lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 185,000 shares of the biopharmaceutical company’s stock after selling 48,000 shares during the quarter. Bp Plc’s holdings in Gilead Sciences were worth $13,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Welch Investments LLC bought a new stake in Gilead Sciences during the third quarter valued at about $108,000. Wealthcare Advisory Partners LLC bought a new stake in Gilead Sciences during the third quarter valued at about $133,000. Horan Capital Advisors LLC. bought a new stake in Gilead Sciences during the third quarter valued at about $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences during the second quarter valued at about $147,000. Finally, Hanson & Doremus Investment Management boosted its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. 77.83% of the stock is owned by institutional investors.
In other Gilead Sciences news, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $80.09, for a total value of $467,164.97. Following the sale, the director now owns 58,452 shares in the company, valued at $4,681,420.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 436,101 shares of company stock worth $34,541,560. Company insiders own 1.30% of the company’s stock.
Shares of GILD stock opened at $76.92 on Wednesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The company has a market capitalization of $104,456.84, a PE ratio of 22.10, a P/E/G ratio of -1.83 and a beta of 1.24. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the previous year, the business earned $2.70 earnings per share. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.96%. Gilead Sciences’s dividend payout ratio is 65.52%.
GILD has been the subject of a number of recent analyst reports. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a research note on Wednesday, January 17th. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Maxim Group set a $94.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Wells Fargo raised Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $88.61.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.